Dysregulated lipid metabolism blunts the sensitivity of cancer cells to EZH2 inhibitor
Summary: Background: Sensitivity has been a key issue for Enhancer of zeste homolog 2 (EZH2) inhibitors in cancer therapy.The EZH2 inhibitor EPZ-6438 was first approved by the US Food and Drug Administration (FDA) in 2020.However, its inadequate anti-cancer activity in solid tumors limits its clinical application.In this study, we utilized the mult